Clinical Trials

294 enrolled

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

NCT05064280 2026-04-16

Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases

104 enrolled

CNS

Brain Neoplasms, Neoplasms

NCT06669572 2026-04-15

Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment

35 enrolled

Tumor-Agnostic

Carcinoma, Squamous Cell

NCT07530445 2026-04-15

Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer

40 enrolled

Biliary Tract Neoplasms

NCT06880523 2026-04-14

SLIDE-HCC

140 enrolled

Carcinoma, Hepatocellular

NCT04745988 2026-04-09

An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer

43 enrolled

Stomach Neoplasms

NCT05696548 2026-04-09

Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)

51 enrolled

EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

NCT07518706 2026-04-09

Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin

60 enrolled

Carcinoma, Hepatocellular

NCT04869137 2026-04-08

Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma

26 enrolled 9 charts

Dermatologic

Skin Neoplasms, Carcinoma, Merkel Cell

NCT05327686 2026-04-08

SAMURAI

240 enrolled

Carcinoma, Renal Cell

NCT05286437 2026-04-06

LaPemERLA

40 enrolled

Breast

Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer

NCT07290894 2026-04-02

MITO VULVA-01

80 enrolled

Vulvar Neoplasms

NCT07495579 2026-03-27

REVIVE

146 enrolled

Carcinoma, Hepatocellular

NCT07493668 2026-03-25

FLEX-HCC

80 enrolled

Carcinoma, Hepatocellular

NCT03950609 2026-03-19

Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors

36 enrolled

EndocrineNET

Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1

NCT06036836 2026-03-19

MK-4280A-010

Phase 2 Completed

163 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT05746208 2026-03-17

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

29 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT07092514 2026-03-17

Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)

34 enrolled

Head & Neck

Thyroid Neoplasms

NCT05824468 2026-03-10

Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer

Uterine Cervical Neoplasms

NCT05824481 2026-03-10

Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer

32 enrolled

Endometrial Neoplasms

NCT07460206 2026-03-10

PRELUDE

108 enrolled

Carcinoma, Renal Cell

NCT06859684 2026-03-09

HAIC-quad

25 enrolled

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

NCT05012371 2026-03-05

Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer

90 enrolled

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT06114940 2026-03-05

PLUTO

Phase 2 Terminated

17 enrolled

Carcinoma, Renal Cell

NCT04321954 2026-02-27

Lenvatinib in Locally Advanced Invasive Thyroid Cancer

EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT07432568 2026-02-25

A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC

Cholangiocarcinoma

NCT04710628 2026-02-19

PECATI

Phase 2 Completed

43 enrolled

Thoracic

Thymoma

NCT07417501 2026-02-18

Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 Amplification

60 enrolled

Other solid neoplasm

Solid Tumors

NCT04171622 2026-02-17

Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer

25 enrolled

EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

NCT07412054 2026-02-17

BLP-HCC

234 enrolled

Carcinoma, Hepatocellular

NCT04848337 2026-02-12

PLANE-PC

45 enrolled 8 charts

EndocrineNET

Neuroendocrine Tumors

NCT04781088 2026-02-11

Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

38 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT07389629 2026-02-05

Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC

25 enrolled

Carcinoma, Renal Cell

NCT07384416 2026-02-04

Single-Arm Trial of QL1706, Lenvatinib, and Nab-Paclitaxel for Advanced Refractory Penile Cancer

47 enrolled

Penile Neoplasms

NCT05113186 2026-01-29

LENVABLA

32 enrolled

Carcinoma, Hepatocellular

NCT07368985 2026-01-27

Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer

87 enrolled

Adenocarcinoma, Uterine Cervical Neoplasms

NCT05036434 2026-01-23

ACCOMPLISH

Endocrine

Adrenocortical Carcinoma

NCT05846724 2026-01-22

PULSAR

Phase 2 Withdrawn

Sarcoma

Sarcoma, Kaposi

NCT07359053 2026-01-22

MAGNATE-S

46 enrolled

Sarcoma

NCT05254847 2026-01-20

Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC

Phase 2 Completed

65 enrolled